Bicycle Therapeutics plc (BCYC)

Market Cap	737.60M
Revenue (ttm)	22.52M
Net Income (ttm)	-139.99M
Shares Out	36.71M
EPS (ttm)	-4.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,674
Open	21.75
Previous Close	21.55
Day's Range	20.09 - 21.75
52-Week Range	18.84 - 33.49
Beta	0.72
Analysts	Strong Buy
Price Target	49.00 (+143.9%)
Earnings Date	Nov 2, 2023

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibito...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 236
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC

Financial Performance

In 2022, BCYC's revenue was $14.46 million, an increase of 23.65% compared to the previous year's $11.70 million. Losses were -$112.72 million, 68.7% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for BCYC stock is "Strong Buy." The 12-month stock price forecast is $49.0, which is an increase of 143.90% from the latest price.

Price Target

$49.0

(143.90% upside)

Analyst Consensus: Strong Buy